Genesis Therapeutics

Genesis Therapeutics is a biotechnology firm that specializes in AI-powered drug discovery, focusing on unlocking novel protein targets and exploring untapped chemical spaces. The company employs advanced techniques such as 3D spatial graph modeling and cutting-edge molecular simulation to generate novel drug candidates. Recently, Genesis Therapeutics closed an oversubscribed $200M Series B funding round, supported by notable investors like Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVIDIA Ventures, and BlackRock. Additionally, the company has entered into a significant AI discovery deal with Eli Lilly, which includes $20M in upfront cash and could potentially reach a total value of $670M.